Toro Neurovascular has announced an exclusive distribution partnership with Kaneka Medical America for Toro’s novel neurovascular catheter portfolio in the US market, pending regulatory clearance.
“Partnering with Kaneka accelerates our mission to equip physicians with tools that make the most challenging neurovascular procedures more predictable and controlled,” said Hyung Posalit, chief executive officer (CEO) of Toro. “Kaneka’s strong commercial infrastructure and shared commitment to clinical excellence make them an ideal partner to bring our technology to market swiftly, and at scale.”
The collaboration will bring Toro’s next-generation catheter platform—engineered for superior trackability, distal support and stability during complex interventions, according to the company—to clinicians treating ischaemic and haemorrhagic stroke across the USA. Toro’s novel catheter platform is designed to address unmet clinical needs with a focus on performance, deliverability and versatility across a wide range of neurovascular interventions, as per a press release.
“Toro’s catheter technologies complement and strengthen our existing neurovascular portfolio, giving us the opportunity to offer a broader spectrum of solutions to patients suffering from neurovascular disease,” said Ken Toda, president of Kaneka Medical America. “Together, we aim to deliver innovations that help improve procedural precision and patient care.”
“Our partnership with Toro reflects Kaneka’s culture of innovation and shared commitment to lasting impact in neurovascular care,” added Rob Abrams, chief strategy officer for Kaneka Medical America.
To strengthen its commercialisation efforts, Toro has also appointed Marc Paris as its chief commercial officer. Toro’s recent release notes that Paris brings more than two decades of leadership in medical device commercialisation and will oversee market launch strategy in collaboration with Kaneka.
“Joining Toro Neurovascular at this exciting time, especially with our partnership with Kaneka, is a tremendous opportunity,” Paris commented. “Toro’s engineering team has developed a technology that truly advances the standard of neurovascular catheter design.”
